Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma

Leukemia

Volumn 28, Issue 4, 2014, Pages 894-903

  Wang, X ^a   Yan, Z ^b   Fulciniti, M ^c   Li, Y ^a   Gkotzamanidou, M ^c   Amin, S B ^b   Shah, P K ^b   Zhang, Y ^a   Munshi, N C ^c   Li, C ^a,b  

^a TONGJI UNIVERSITY   (China)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cell cycle arrest; coexpression; hyperdiploid; multiple myeloma

Indexed keywords

ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MYC PROTEIN; TRANSCRIPTION FACTOR HOXA9; TRANSCRIPTION FACTOR SP1;

ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DIPLOIDY; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; NONHYPERDIPLOID MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION;

BAYES THEOREM; CELL CYCLE CHECKPOINTS; CYCLIN-DEPENDENT KINASE 2; E2F1 TRANSCRIPTION FACTOR; ESTROGEN RECEPTOR ALPHA; HOMEODOMAIN PROTEINS; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MULTIPLE MYELOMA; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS;

EID: 84898475000     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.233     Document Type: Article

References (60)

1. Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
2. Anderson KC, Carrasco RD. Pathogenesis of myeloma. Annu Rev Pathol 2011; 6: 249-274.
3. Fonseca R, Bergsagel PL, Drach J, Shaughnessy J, Gutierrez N, Stewart AK et al. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia 2009; 23: 2210-2221.
4. Wuilleme S, Robillard N, Lode L, Magrangeas F, Beris H, Harousseau JL et al. Ploidy, as detected by fluorescence in situ hybridization, defines different subgroups in multiple myeloma. Leukemia 2005; 19: 275-278. (Pubitemid 40220593)
5. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296-303. (Pubitemid 40967205)
6. Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23: 961-970.
7. Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res 2007; 67: 2982-2989. (Pubitemid 46724834)
8. Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL et al. Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations. Leukemia 2006; 20: 807-813.
9. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F et al. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 2007; 136: 565-573. (Pubitemid 46148193)
10. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M et al. Oncogenic mutations of ALK kinase in neuroblastoma. Nature 2008; 455: 971-974.
11. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
12. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012; 26: 1829-1841.
13. Levine AJ, Oren M. The first 30 years of p53: growing ever more complex. Nat Rev Cancer 2009; 9: 749-758.
14. Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia 2009; 23: 10-24.
15. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545-15550. (Pubitemid 41528093)
17. Kitada M, Rowitch DH. Transcription factor co-expression patterns indicate heterogeneity of oligodendroglial subpopulations in adult spinal cord. Glia 2006; 54: 35-46. (Pubitemid 43980032)
18. Watson M. CoXpress: differential co-expression in gene expression data. BMC Bioinform 2006; 7: 509.
19. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 2005 4 (Article 17).
20. de la Fuente A. From 'differential expression' to 'differential networking'-identification of dysfunctional regulatory networks in diseases. Trends Genet 2010; 26: 326-333.
21. Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A et al. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116: 2543-2553.
22. Agnelli L, Bicciato S, Fabris S, Baldini L, Morabito F, Intini D et al. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. Haematologica 2007; 92: 56-65. (Pubitemid 46232658)
23. Li Y, Wang X, Zheng H, Wang C, Minvielle S, Magrangeas F et al. Classify hyperdiploidy status of multiple myeloma patients using gene expression profiles. PLoS One 2013; 8: e58809.
24. Yan Z, Shah PK, Amin SB, Samur MK, Huang N, Wang X et al. Integrative analysis of gene and miRNA expression profiles with transcription factor-miRNA feedforward loops identifies regulators in human cancers. Nucleic Acids Res 2012; 40: e135.
25. Anderson TW. An Introduction To Multivariate Statistical Analysis3rd edn (Wiley-Interscience: Hoboken, NJ, USA, 2003.
26. Choi JK, Yu U, Yoo OJ, Kim S. Differential coexpression analysis using microarray data and its application to human cancer. Bioinformatics 2005; 21: 4348-4355. (Pubitemid 41782924)
27. Brocke-Heidrich K, Kretzschmar AK, Pfeifer G, Henze C, Loffler D, Koczan D et al. Interleukin-6-dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family-independent survival pathway closely associated with Stat3 activation. Blood 2004; 103: 242-251. (Pubitemid 38029945)
28. Largo C, Alvarez S, Saez B, Blesa D, Martin-Subero JI, Gonzalez-Garcia I et al. Identification of overexpressed genes in frequently gained/amplified chromosome regions in multiple myeloma. Haematologica 2006; 91: 184-191.
29. Lin CY, Loven J, Rahl PB, Paranal RM, Burge CB, Bradner JE et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell 2012; 151: 56-67.
30. Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C et al. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res 2011; 17: 6500-6509.
31. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010; 70: 440-446.
32. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799. (Pubitemid 39070849)
33. Croce CM. Oncogenes and cancer. N Engl J Med 2008; 358: 502-511. (Pubitemid 351185806)
34. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS et al. The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 2003; 278: 26589-26596. (Pubitemid 36876803)
35. Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008; 133: 1019-1031. (Pubitemid 351787746)
36. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007; 26: 3291-3310. (Pubitemid 46763022)
37. Thomas C, Gustafsson JA. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer 2011; 11: 597-608.
38. Tan NY, Khachigian LM. Sp1 phosphorylation and its regulation of gene transcription. Mol Cell Biol 2009; 29: 2483-2488.
39. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009; 9: 785-797.
40. Lin CY, Vega VB, Thomsen JS, Zhang T, Kong SL, Xie M et al. Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet 2007; 3: e87.
41. Dai Y, Chen S, Shah R, Pei XY, Wang L, Almenara JA et al. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo. Blood 2011; 117: 1947-1957.
42. Castro-Rivera E, Samudio I, Safe S. Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 2001; 276: 30853-30861.
43. Bartusel T, Schubert S, Klempnauer KH. Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. Gene 2005; 351: 171-180. (Pubitemid 40732629)
44. Sola B, Renoir JM. Antiestrogenic therapies in solid cancers and multiple myeloma. Curr Mol Med 2006; 6: 359-368. (Pubitemid 43840603)
45. Kim K, Thu N, Saville B, Safe S. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells. Mol Endocrinol 2003; 17: 804-817. (Pubitemid 36546213)
46. Louie MC, McClellan A, Siewit C, Kawabata L. Estrogen receptor regulates E2F1 expression to mediate tamoxifen resistance. Mol Cancer Res 2010; 8: 343-352.
47. Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC et al. Initial genome sequencing and analysis of multiple myeloma. Nature 2011; 471: 467-472.
48. Whelan JT, Ludwig DL, Bertrand FE. HoxA9 induces insulin-like growth factor-1 receptor expression in B-lineage acute lymphoblastic leukemia. Leukemia 2008; 22: 1161-1169. (Pubitemid 351833783)
49. Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia 2001; 15: 1689-1695. (Pubitemid 33061834)
50. Romana SP, Radford-Weiss I, Ben Abdelali R, Schluth C, Petit A, Dastugue N et al. NUP98 rearrangements in hematopoietic malignancies: a study of the Groupe Francophone de Cytogenetique Hematologique. Leukemia 2006; 20: 696-706.
51. Willoughby Sr JA, Sundar SN, Cheung M, Tin AS, Modiano J, Firestone GL. Artemisinin blocks prostate cancer growth and cell cycle progression by disrupting Sp1 interactions with the cyclin-dependent kinase-4 (CDK4) promoter and inhibiting CDK4 gene expression. J Biol Chem 2009; 284: 2203-2213.
52. Levin ER. Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol 2005; 19: 1951-1959. (Pubitemid 41124194)
53. Clemons M, Danson S, Howell A. Tamoxifen ('Nolvadex'): a review. Cancer Treat Rev 2002; 28: 165-180. (Pubitemid 35244125)
54. Otsuki T, Yamada O, Kurebayashi J, Moriya T, Sakaguchi H, Kunisue H et al. Estrogen receptors in human myeloma cells. Cancer Res 2000; 60: 1434-1441. (Pubitemid 30152018)
55. Gauduchon J, Gouilleux F, Maillard S, Marsaud V, Renoir JM, Sola B. 4-Hydroxytamoxifen inhibits proliferation of multiple myeloma cells in vitro through down-regulation of c-Myc, up-regulation of p27Kip1, and modulation of Bcl-2 family members. Clin Cancer Res 2005; 11: 2345-2354. (Pubitemid 40490196)
56. Wang W, Dong L, Saville B, Safe S. Transcriptional activation of E2F1 gene expression by 17beta-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol Endocrinol 1999; 13: 1373-1387. (Pubitemid 30645293)
57. Matys V, Kel-Margoulis OV, Fricke E, Liebich I, Land S, Barre-Dirrie A et al. TRANSFAC and its module TRANSCompel: transcriptional gene regulation in eukaryotes. Nucleic Acids Res 2006; 34: D108-D110.
58. Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM. A census of human transcription factors: function, expression and evolution. Nat Rev Genet 2009; 10: 252-263.
59. Margolin AA, Nemenman I, Basso K, Wiggins C, Stolovitzky G, Dalla Favera R et al. ARACNE: an algorithm for the reconstruction of gene regulatory networks in a mammalian cellular context. BMC Bioinformatics 2006; 7(Suppl 1): S7.
60. Fujiwara T, Hiramatsu M, Isagawa T, Ninomiya H, Inamura K, Ishikawa S et al. ASCL1-coexpression profiling but not single gene expression profiling defines lung adenocarcinomas of neuroendocrine nature with poor prognosis. Lung Cancer 2012; 75: 119-125.